TY - JOUR
T1 - Pharmacological management of bipolar disorder
T2 - Japanese expert consensus
AU - Medical Education Panel of the Japanese Society of Clinical Neuropsychopharmacology
AU - Sakurai, Hitoshi
AU - Kato, Masaki
AU - Yasui-Furukori, Norio
AU - Suzuki, Takefumi
AU - Baba, Hajime
AU - Watanabe, Koichiro
AU - Inada, Ken
AU - Kishida, Ikuko
AU - Sugawara Kikuchi, Yuka
AU - Kikuchi, Toshiaki
AU - Katsuki, Asuka
AU - Uchida, Hiroyuki
N1 - Funding Information:
Dr Sakurai reports grants from Japanese Society of Clinical Neuropsychopharmacology, grants from Uehara Memorial Foundation, personal fees from Dainippon‐Sumitomo Pharma, personal fees from Otsuka Pharmaceutical, personal fees from Meiji‐Seika Pharma, personal fees from Eli Lilly, personal fees from Tanabe Mitsubishi Pharma, personal fees from Yoshitomi Yakuhin, outside the submitted work. Dr Kato has received grant funding from Japan Society for the Promotion of Science, SENSHIN Medical Research Foundation and Japan Research Foundation for Clinical Pharmacology, and speaker's honoraria from Dainippon‐Sumitomo Pharma, Otsuka, Meiji‐Seika Pharma, Eli Lilly, MSD KK, GlaxoSmithkline, Pfizer, Janssen Pharmaceutical, Shionogi, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical and Ono Pharmaceutical. Dr Norio Yasui‐Furukori has been a speaker for Dainippon‐Sumitomo Pharmaceutical, Mochida Pharmaceutical, Otsuka Pharmaceutical and MSD for other studies within the past three years. The funders had no role in the study design, data collection and analysis, the decision to publish, or the preparation of the manuscript. Dr Suzuki has received manuscript or speaker's fees from Astellas, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Elsevier Japan, Janssen Pharmaceuticals, Kyowa Yakuhin, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Novartis, Otsuka Pharmaceutical, Shionogi, Tsumura, Wiley Japan, and Yoshitomi Yakuhin, and research grants from Eisai, Mochida Pharmaceutical, Meiji Seika Pharma and Shionogi. Dr Baba reports grants from Novartis, personal fees from MSD, personal fees from Otsuka, personal fees from Dainippon Sumitomo, personal fees from Meiji Seika, personal fees from Eli Lilly, personal fees from Yoshitomi, personal fees from Janssen, personal fees from Kyowa, personal fees from Mitsubishi Tanabe, personal fees from Ono, personal fees from Pfizer, personal fees from Takeda, outside the submitted work. Dr Watanabe has received manuscript fees or speaker's honoraria from Daiichi Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutical, Kyowa Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Shionogi, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, Yoshitomi, and has received research/grant support from Astellas Pharma, Daiichi Sankyo, Eisai, MSD, Mitsubishi Tanabe Pharma, Meiji Seika Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, Sumitomo Dainippon Pharma, and is a consultant of Eisai, Eli Lilly, Kyowa Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Taisho Toyama Pharmaceutical, and Takeda Pharmaceutical. Dr Inada reports personal fees from Dainippon Sumitomo Pharma, personal fees from Eisai, personal fees from Eli Lilly Japan, personal fees from Janssen pharmaceutical, personal fees from Meiji‐Seika Pharmaceutical, personal fees from Mochida, grants and personal fees from MSD, personal fees from Novartis, personal fees from Otsuka Pharmaceutical, personal fees from Shionogi, personal fees from Tanabe‐Mitsubishi Pharma, personal fees from Yoshitomi Yakuhin, outside the submitted work. DrKishida and Dr Yuka Sugawara Kikuchi have nothing to disclose. Dr Toshiaki Kikuchi reports personal fees from Otsuka Pharmaceutical, personal fees from Dainippon‐Sumitomo, personal fees from Eli Lilly, personal fees from Mochida, personal fees from Meiji‐Seika, personal fees from Yoshitomi‐Yakuhin, personal fees from Takeda, personal fees from MSD, personal fees from Pfizer, outside the submitted work. Dr Katsuki reports personal fees from Dainippon Sumitomo Pharma. Dr Uchida has received grants from Eisai, Otsuka Pharmaceutical, Dainippon‐Sumitomo Pharma, and Meiji‐Seika Pharmaceutical; speaker's honoraria from Otsuka Pharmaceutical, Eli Lilly, Yoshitomi Yakuhin, Dainippon‐Sumitomo Pharma, Meiji‐Seika Pharma, and MSD; and advisory panel payments from Dainippon‐Sumitomo Pharma within the past three years.
Funding Information:
This work was supported by the GlaxoSmithKline medical education project grant. The authors thank AsakiMatsuzaki for his support in the previous presentation.
Publisher Copyright:
© 2020 The Authors. Bipolar Disorders published by John Wiley & Sons Ltd
PY - 2020/12
Y1 - 2020/12
N2 - Objectives: The aim of this study was to develop a consensus guideline by certified experts of the Japanese Society of Clinical Neuropsychopharmacology on the psychopharmacological treatment for bipolar disorders I and II (BP-I and BP-II), in order to fill the gap in the literature and provide more concrete guidance for challenging and controversial real-world situations. Methods: Experts were asked to assess treatment options regarding 19 clinical situations of bipolar disorder with a nine-point Likert scale (one = “disagree” and nine = “agree”). According to the responses from 119 experts, the options were categorized into the first-, second-, and third-line treatments. Results: For the treatment of BP-I, lithium monotherapy was categorized as a first-line treatment for manic episodes (mean ± standard deviation score, 7.0 ± 2.2), depressive episodes (7.1 ± 2.0), and the maintenance phase (7.8 ± 1.8). Combination therapy of lithium and an atypical antipsychotic was endorsed for manic episodes (7.7 ± 1.7), depressive episodes with (7.1 ± 2.0) and without mixed features (6.9 ± 2.2), and the maintenance phase (6.9 ± 2.1). Similarly, in BP-II, lithium monotherapy was categorized as a first-line treatment for hypomanic episodes (7.3 ± 2.2), depressive episodes (7.0 ± 2.2), and the maintenance phase (7.3 ± 2.3), while combination therapy of lithium and an atypical antipsychotic was recommended for hypomanic episodes (6.9 ± 2.4).No antipsychotic monotherapy or antidepressant treatment was categorized as a first-line treatment for any type of episode. Conclusions: These recommendations reflect the current evidence and represent the experts' consensus on using lithium for the treatment of bipolar disorder. Clinicians should consider the effectiveness and adverse effects of antipsychotic and antidepressant medications for the treatment of bipolar disorder.
AB - Objectives: The aim of this study was to develop a consensus guideline by certified experts of the Japanese Society of Clinical Neuropsychopharmacology on the psychopharmacological treatment for bipolar disorders I and II (BP-I and BP-II), in order to fill the gap in the literature and provide more concrete guidance for challenging and controversial real-world situations. Methods: Experts were asked to assess treatment options regarding 19 clinical situations of bipolar disorder with a nine-point Likert scale (one = “disagree” and nine = “agree”). According to the responses from 119 experts, the options were categorized into the first-, second-, and third-line treatments. Results: For the treatment of BP-I, lithium monotherapy was categorized as a first-line treatment for manic episodes (mean ± standard deviation score, 7.0 ± 2.2), depressive episodes (7.1 ± 2.0), and the maintenance phase (7.8 ± 1.8). Combination therapy of lithium and an atypical antipsychotic was endorsed for manic episodes (7.7 ± 1.7), depressive episodes with (7.1 ± 2.0) and without mixed features (6.9 ± 2.2), and the maintenance phase (6.9 ± 2.1). Similarly, in BP-II, lithium monotherapy was categorized as a first-line treatment for hypomanic episodes (7.3 ± 2.2), depressive episodes (7.0 ± 2.2), and the maintenance phase (7.3 ± 2.3), while combination therapy of lithium and an atypical antipsychotic was recommended for hypomanic episodes (6.9 ± 2.4).No antipsychotic monotherapy or antidepressant treatment was categorized as a first-line treatment for any type of episode. Conclusions: These recommendations reflect the current evidence and represent the experts' consensus on using lithium for the treatment of bipolar disorder. Clinicians should consider the effectiveness and adverse effects of antipsychotic and antidepressant medications for the treatment of bipolar disorder.
UR - http://www.scopus.com/inward/record.url?scp=85087294337&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087294337&partnerID=8YFLogxK
U2 - 10.1111/bdi.12959
DO - 10.1111/bdi.12959
M3 - Article
C2 - 32558145
AN - SCOPUS:85087294337
VL - 22
SP - 822
EP - 830
JO - Bipolar Disorders
JF - Bipolar Disorders
SN - 1398-5647
IS - 8
ER -